PharmaNet Development Group, announced that it is collaborating with the Cancer Immunotherapy Trials Network (CITN) in order to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.
"We are thrilled to collaborate with the Cancer Immunotherapy Trials Network multi-investigator team," commented Anthony Maida, PhD, MA, MBA, Vice President, Clinical Research and General Manager, Oncology. "The association allows us to identify oncology centers of excellence and thought leadersto collaborate on the development of cutting-edge therapeutics."
PharmaNet has been conducting clinical studies for oncology products since 1996 and has a team that includes on-staff oncologists, dedicated to the development of cancer treatments. The Company has experience in the development of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types. Two hundred local, regional and global oncology clinical trials have been awarded to PharmaNet in the past five years, including eleven registration programs, seven which resulted in NDA/MAA approvals.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.